IP Library Granted Patent US 11,739,291
Granted Patent B2
US 11,739,291 · App. 16/607,665 · Granted Aug 29, 2023

3-dimensional (3D) tissue-engineered muscle for tissue restoration

Inventors: Sherry L. Voytik-Harbin (Zionsville, IN); Stacey L. Halum (Indianapolis, IN); Sarah Brookes (West Lafayette, IN); Hongji Zhang (Naperville, IL)
Assignee: Purdue Research Foundation
C12N5/0068C07K14/78C12N5/0062C12N5/0652C12N5/0696C12N2500/34C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,291
App. No.
16/607,665
Granted
Aug 29, 2023
Kind
B2
Abstract

The present disclosure provides solid collagen constructs and tissue compositions, wherein a polymerizable collagen solution or suspension is extruded in the presence or absence of cells to formed an aligned architecture comprising solid collagen constructs such as those made with fibrillar collagen. Methods of using and of manufacturing solid collagen constructs and tissue compositions, where the component collagen is solid fibrillar collagen and cells are preferentially aligned, are also provided.

Claims (18)

1. A collagen composition comprising a synthetic fibrillar collagen network having a uniform density of aligned polymerized oligomeric collagen fibrils throughout said network.

2. The collagen composition of claim 1 further comprising cells.

3. The collagen composition of claim 2 , wherein the cells are stem cells, progenitor cells, motor endplate-expressing muscle progenitor cells, or a combination thereof.

4. The collagen composition of claim 2 , wherein the cells are muscle, skeletal muscle, nerve, tendon, or ligament cells.

5. A tissue implant for human or veterinary use comprising the collagen composition of claim 2 .

6. The collagen composition of claim 2 , wherein the cells are embedded within the fibrillar collagen network.

7. A tissue implant for human or veterinary use comprising the collagen composition of claim 6 .

8. The tissue implant of claim 7 , wherein the tissue implant comprises muscle, skeletal muscle, nerve, tendon, or ligament cells.

9. The tissue implant of claim 7 , wherein the cells are one or more of muscle progenitor cells, motor endplate-expressing muscle progenitor cells, or adipose-derived stem cells.

10. The collagen composition of claim 6 , wherein the cells are muscle, skeletal muscle, nerve, tendon, or ligament cells.

11. The collagen composition of claim 1 , wherein the polymerized oligomeric collagen fibrils consist of Type I oligomeric collagen.

12. A tissue implant for human or veterinary use comprising the collagen composition of claim 1 .

13. A synthetic fibrillar collagen network, having a uniform density of aligned polymerized oligomeric collagen fibrils, said network prepared by a process comprising extruding a polymerizable oligomeric collagen solution under conditions permissive to polymerization of the oligomeric collagen to form said fibrillar collagen network having a uniform density of polymerized oligomeric collagen fibrils throughout said network, wherein the polymerized oligomeric collagen fibrils are aligned.

14. The synthetic fibrillar collagen network of claim 13 , wherein the polymerizable oligomeric collagen solution further comprises cells, and said cells are attached to said fibrillar collagen network.

15. The synthetic fibrillar collagen network of claim 14 , wherein the cells are stem cells, progenitor cells, motor endplate-expressing muscle progenitor cells, or a combination thereof.

16. A process comprising extruding a polymerizable oligomeric collagen solution to form a solid collagen construct wherein the solid collagen construct comprises a uniform density of aligned collagen fibrils.

17. The process of claim 16 , wherein the polymerizable oligomeric collagen solution further comprises cells.

18. The process of claim 17 , wherein the cells are stem cells, progenitor cells, motor-endplate expressing muscle progenitor cells, or a combination thereof.

Continuity (2)
Provisional Application 62489849 · Apr 25, 2017
Related Publication 20200190466A1 · Jun 18, 2020
Cited By (3)
US 12,343,450 US 12,458,669 US 12,708,696